Nomograms May Be Useful for Predicting Survival Survival in Non-metastatic Osteosarcoma
the Cancer Therapy Advisor take:
Age, tumor site, and histologic response were determined to be stronger influences on metastasis-free survival (MFS) and overall survival (OS) for patients with nonmetastatic osteosarcoma compared to sex, tumor size, and pathologic fracture, according to an article published online in the journal Cancer.
A total of 1,070 patients who received neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma were studied.
The authors developed multivariate nomograms based on data from Japanese patients (n=557). The nomograms were developed to estimate the probability of MFS and OS 3 and 5 years post-diagnosis using six clinical and pathologic variables.
The nomogram model was validated internally for discrimination and also validated externally using an independent patient sample from Korea (n=513).
Results showed factors with stronger influences on MFS and OS included a patient’s age, tumor location, and histologic response, compared to patient’s sex, tumor size, or pathologic fracture.
The authors concluded that the nomograms predicted the probability of both MFS (concordance index, 0.631) and OS (concordance index, 0.679) well.MFS had a concordance index of 0.682 for external validation, and OS had an index of 0.665.
The study suggests its findings verify the usefulness of nomograms for predicting MFS and OS and for assessing postoperative prognosis.
Age, tumor site, and histologic response determined to be stronger influences on metastasis-free, overall survival for nonmetastatic osteosarcoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT
- Additional FDA Approval for Olaparib Tablets in Ovarian Cancer
- Besponsa Approved for B-cell Acute Lymphoblastic Leukemia